SCHEMBL5656944

SCHEMBL5656944

Nc1cc(Cl)cc2cnccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 4/20 0.55
CHUK O15111 3/20 0.54
LMNA P02545 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
GAA P10253 1/20 0.45
NR4A2 P43354 1/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44
RAD52 P43351 1/20 0.44
CLK1 P49759 1/20 0.44
CDK5 Q00535 1/20 0.44
CDK5R1 Q15078 1/20 0.44
AXL P30530 1/20 0.39
EP300 Q09472 1/20 0.39
KAT2B Q92831 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29787086 0.80 CHUK (0.50) IMPDH2CHUKLMNACYP1A2CYP3A4
SCHEMBL2243252 0.80 CHUK (0.50) IMPDH2CHUKLMNACYP1A2CYP3A4
SCHEMBL5659114 0.78 LMNA (0.55) IMPDH2CHUKLMNACYP1A2CYP3A4
Hydrochloric Acid SCHEMBL2240661 0.78 CHUK (0.49) IMPDH2CHUKLMNACYP1A2CYP3A4
SCHEMBL3326564 0.76 PRKCH (0.55) IMPDH2LMNACYP1A2CYP3A4CYP2D6
SCHEMBL30905977 0.74 NR4A2 (0.44) IMPDH2LMNACYP1A2CYP3A4CYP2D6
SCHEMBL27932280 0.73 IMPDH2 (0.50) IMPDH2CHUKLMNACYP1A2CYP3A4
SCHEMBL5656993 0.73 CYP1A2 (0.49) IMPDH2CHUKLMNACYP1A2CYP3A4
SCHEMBL30218963 0.73 CYP1A2 (0.49) IMPDH2CHUKLMNACYP1A2CYP3A4
SCHEMBL5659020 0.73 CYP1A2 (0.51) IMPDH2CHUKLMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113227054-B ROCK kinase inhibitors 切尔韦洛治疗有限责任公司 2025-04-11 CN disclosed
EP-3877364-B1 ROCK KINASE INHIBITORS Cervello Therapeutics LLC (US) 2024-08-21 EP disclosed
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 US disclosed
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 US disclosed
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 US disclosed
US-20220119406-A1 SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS Cervello Therapeutics LLC (US) 2022-04-21 US disclosed
US-20220119406-A1 SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS Cervello Therapeutics LLC (US) 2022-04-21 US disclosed
US-11248004-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2022-02-15 US disclosed
US-11248004-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2022-02-15 US disclosed
EP-3877364-A1 ROCK KINASE INHIBITORS Cervello Therapeutics, LLC (US) 2021-09-15 EP disclosed
CN-113227054-A ROCK kinase inhibitors 切尔韦洛治疗有限责任公司 2021-08-06 CN disclosed
US-20200262844-A1 ROCK KINASE INHIBITORS CERVELLO THERAPEUTICS, LLC. 2020-08-20 US disclosed
US-20200262844-A1 ROCK KINASE INHIBITORS CERVELLO THERAPEUTICS, LLC. 2020-08-20 US disclosed
US-10745381-B2 Substituted isoquinolines and phthalazines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2020-08-18 US disclosed
US-20200140412-A1 ROCK KINASE INHIBITORS CERVELLO THERAPEUTICS, LLC. 2020-05-07 US disclosed
US-7285563-B2 Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain MERCK SHARP & DOHME LTD. (GB) 2007-10-23 US disclosed
US-20050107388-A1 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain MERCK SHARP & DOHME LTD. (GB) 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10745381-B2 Substituted isoquinolines and phthalazines as rock kinase inhibitors ROCK1, ROCK2, CIT IMPDH2 695/4885CHUK 275/4885LMNA 2467/4885
US-11248004-B2 Substituted isoquinolines as rock kinase inhibitors ROCK1, ROCK2, CIT IMPDH2 619/4885CHUK 261/4885LMNA 1820/4885
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors ROCK1, ROCK2, CIT IMPDH2 619/4885CHUK 261/4885LMNA 1820/4885
US-20050107388-A1 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain ARRB1, OPRL1, CNR1 IMPDH2 3396/4885CHUK 581/4885LMNA 2921/4885
US-20200140412-A1 ROCK KINASE INHIBITORS ROCK1, ROCK2, RHOA IMPDH2 2616/4885CHUK 244/4885LMNA 1600/4885
US-20200262844-A1 ROCK KINASE INHIBITORS ROCK1, ROCK2, RHOA IMPDH2 2616/4885CHUK 244/4885LMNA 1600/4885
US-20220119406-A1 SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS ROCK1, ROCK2, CIT IMPDH2 619/4885CHUK 261/4885LMNA 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.